Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jardiance after TAVI in aortic stenosis with preserved LVEF
jRCT1031250190Recruiting
- Sponsor
- Chiba University Hospital
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of empagliflozin in aortic stenosis (AS) (2 arms), sponsored by Chiba University Hospital. Primary endpoint: Change in E/e' at 24 weeks after treatment initiation. Started Aug 2025; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
aortic stenosis (AS)
Beyond the preview
Go deeper on jRCT1031250190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250190.